
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 0.76 | 0.76 | 0.00 |
Shares | 91.08 | 91.08 | 0.00 |
Convertible | 0.12 | 0.12 | 0.00 |
Other | 8.03 | 8.03 | 0.00 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 22.69 | 18.81 |
Price to Book | 4.59 | 4.29 |
Price to Sales | 1.72 | 2.29 |
Price to Cash Flow | 18.09 | 15.42 |
Dividend Yield | 0.81 | 1.19 |
5 Years Earnings Growth | 9.15 | 10.59 |
Name | Net % | Category Average |
---|---|---|
Healthcare | 99.91 | 99.59 |
Financial Services | 0.09 | 0.84 |
Number of long holdings: 137
Number of short holdings: 1
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Eli Lilly | US5324571083 | 11.92 | 660.49 | +3.29% | |
Aggregate Miscellaneous Equity | - | 8.03 | - | - | |
Intuitive Surgical | US46120E6023 | 5.81 | 482.35 | +0.87% | |
UnitedHealth | US91324P1021 | 5.08 | 271.81 | +3.91% | |
Stryker | US8636671013 | 4.98 | 378.95 | +0.62% | |
Vertex | US92532F1003 | 3.83 | 395.92 | +2.10% | |
Boston Scientific | US1011371077 | 3.68 | 102.50 | -0.14% | |
argenx ADR | US04016X1019 | 3.33 | 646.60 | +1.42% | |
Danaher | US2358511028 | 3.10 | 209.14 | +1.66% | |
Thermo Fisher Scientific | US8835561023 | 3.06 | 484.79 | +1.55% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
T. Rowe Price Capital Appreciation | 36.88B | 8.84 | 11.39 | 10.81 | ||
T. Rowe Price Blue Chip Growth | 34.32B | 11.70 | 23.40 | 14.89 | ||
T. Rowe Price Capital AppreciationI | 31.43B | 8.90 | 11.53 | - | ||
T. Rowe Price Blue Chip Growth I | 30.85B | 11.79 | 23.56 | - | ||
T. Rowe Price Instl Large Cap Growt | 22.72B | 10.10 | 22.18 | 15.96 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review